Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?

Carlos Diego Holanda Lopes, Anna Spreafico, Daniel V. Araujo

Open source

DOI
10.21037/tcr-2026-1245
Published
2026-08
Container
Translational Cancer Research
Publisher
AME Publishing Company
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21037/tcr-2026-1245,
  title = {Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?},
  author = {Carlos Diego Holanda Lopes and Anna Spreafico and Daniel V. Araujo},
  year = {2026},
  journal = {Translational Cancer Research},
  doi = {10.21037/tcr-2026-1245},
  url = {https://doi.org/10.21037/tcr-2026-1245}
}

RIS

TY  - JOUR
TI  - Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?
AU  - Carlos Diego Holanda Lopes
AU  - Anna Spreafico
AU  - Daniel V. Araujo
PY  - 2026
JO  - Translational Cancer Research
DO  - 10.21037/tcr-2026-1245
UR  - https://doi.org/10.21037/tcr-2026-1245
ER  - 

APA

Lopes, C. D. H., Spreafico, A., & Araujo, D. V. (2026). Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?. Translational Cancer Research. https://doi.org/10.21037/tcr-2026-1245

Source records